Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside

Stephens has initiated coverage on Pyxis Oncology Inc (NASDAQ:PYXS), highlighting the company’s technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, stability, and tolerability.

The analyst points out that Pyxis’ lead drug, PYX-201, is an ADC that targets Extradomain-B Fibronectin (EDB+FN) in the tumor stroma and releases a toxic payload into the tumor microenvironment.

The analyst has initiated with an Overweight rating with a price target of $13.

Stephens notes that the ADC technology has shown strong potential, with recent successes boosting confidence in its market growth.

Also Read: Pyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC ...

Full story available on Benzinga.com